66 results about "Exocrine secretion" patented technology

A method and apparatus for treating a patient's health condition by diverting pancreatic exocrine secretions include a flow diverter of material compatible with chronic residence within a small intestine of the patient. The flow diverter has a cover end and a discharge end. The flow diverter is sized to be placed within the small intestine with the discharge end placed distally from said cover end and with said flow diverter further sized so permit passage of chyme through the small intestine and past the flow diverter. The cover end is sized to cover a discharge papilla of the pancreatic duct. The diverter is adapted to divert at least a portion of pancreatic exocrine secretion from the papilla to the distal discharge end.

The invention relates to methods for generating insulin secreting cells from precursor stem cells or from adult pancreatic exocrine cells. The methods of the invention are useful, for example, for generation of glucose sensitive insulin-secreting beta-cells suitable for transplantation, as well as for in situ development of insulin-secreting cells in a patient in need thereof. Further, the method of the invention relates to methods for preventing premature differentiation of precursor stem cells into insulin-secreting beta-cells. Still further, the invention relates to assay methods for identification of compounds that prevent or activate beta-cell differentiation.

The invention provides application of novel glucagon peptide 1 fatty acid modified or unmodified dimer different in configuration in pancreas protection or hypoglycemic effect during treatment of II-type diabetes. The dimer is formed by connecting two identical GLP-1 monomers containing cysteine through disulfide bond formed by cysteine oxidation. Hypoglycemic duration of GLP-1 dimer is remarkablyprolonged without lowering activity of H-shaped GLP-1 homodimer (the disulfide bond is formed inside peptide chain), in-vivo continuous activity of GLP-1 analogue dimer can last for 19d while in-vivoactivity of liraglutide which is positive control drug is 3d, or in-vivo activity duration is remarkably prolonged when compared with long-acting GLP1 similar peptide which has already been reportedat present, so that technical progress of long-acting GLP1 drug is greatly promoted while convenience is brought to clinical application and popularization of the same. U-shaped homodimer (the disulfide bond is formed at the terminal C of the peptide chain) does not have impact on blood glucose but can obviously protect exocrine portion cells like pancreatic acini and catheters, thereby having a pancreas protecting function.

The present invention relates to methods for screening and modulating the bioavailability of extracellular secretory vimentin. In particular, the present invention provides inhibitors and activators of secretory vimentin including antibodies, small interfering RNAs, and antisense oligonucleotides. The present invention thus provides novel drug targets for enhanced anti-microbial response, and methods of using such modulators to beneficially alter the pathophysiologic effects of secretory vimentin.

A method and device to predict ovulation in a female human by measuring changes in the concentration of a number of ions in eccrine sweat is disclosed. The concentration, or changes in concentration, of one or more ions are determined throughout the day and analyzed against predetermined patterns in order to predict ovulation one to five days in advance. This permits the user to more accurately determine commencement of the fertile phase, which for female humans is generally considered to be about four days prior to ovulation to one day after ovulation. The concentration of the ions measured include sodium (Na+), potassium (K+), ammonium (NH₄+), calcium (Ca₂+), chloride (Cl−) and nitrate (NO₃−). To further increase the accuracy of the reading, a large number of readings can be obtained throughout a day and statistically analyzed to determine the change over time. In addition, the concentration of two or more ions can be obtained to increase accuracy. Ratiometric measurements between two or more ions can be determined to increase accuracy and account for ion accumulation on the skin. Ratiometric measurements between ammonium (NH₄+) and calcium (Ca₂+) have been found to provide more distinct patterns because the concentration of these two ions change in opposite directions during the relevant period preceding ovulation.

The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.

The invention relates the method for producing renovation pigling Langer-hans' insula cell. The method comprises the following steps: 1 choosing donator: choosing health pigling, at sterility opening abdomen, getting pancreatic, removing integument, vessel, connective tissue in Hank`s liquid at 4Deg.C; 2 separating and purifying Langer-hans' insula cell: separating Langer-hans' insula cell from external secretion tissue with finishing machine, centrifuging with Dextran non-sequence density gradient, getting Langer-hans' insula cell; 3 culturing Langer-hans' insula cell: carrying out CO2 culturing with non-serum microballoon carrier, using RPMI-1640 culture liquid, adding fibrin, packaging the Langer-hans' insula cell in the APA biological film to form microsphere, at 37Deg.C, culturing in the CO2 culture box, changing culture liquid every 48 hours, and getting the product.

The invention discloses a construction method of a pancreatic duct epithelial cell and pancreatic acinar cell co-culture system for simulating in vivo microenvironment, and belongs to the technical field of cell biology. The method comprises the steps of inoculating an upper layer of a Transwell dual-layer culturing chamber with original generation pancreatic acinar cells, inoculating a lower layer of the Transwell dual-layer culturing chamber with human pancreatic duct epithelial cells, performing co-culturing, adding sodium taurocholate in the pancreatic duct epithelial cells at the lower layer of the Transwell dual-layer culturing chamber, and observing the vitality, the shape and the apoptosis of the upper layer pancreatic acinar cells. Damage of the pancreatic duct epithelial cells and the pancreatic acinar cells are combined, a non-contact type co-culture manner is adopted for building the pancreatic duct epithelial cell and pancreatic acinar cell co-culture system. In the co-culture system, the two cells can exchange exocytosis secretion substances through Transwell transmembrane. The system can well simulate the pancreatitis induced by cholestasis, and the invention provides an in vitro cell model which can really reflect pancreatitis induced by cholestasis.

Belonging to the technical field of cosmetics, the invention discloses a skin care product for antiallergic repair and a preparation method thereof. The skin care product for antiallergic repair comprises the following components: stem cell exocrine factor lyophilized powder, stem cell inclusion lytic factor lyophilized powder, hyaluronic acid, butanediol, an olive leaf extract, a purslane extract, an evening primrose extract, chamomile hydrolat and purified water. The stem cell secretion factor and stem cell inclusion lytic factor contained in the skin care product provided by the invention are prepared by low temperature freeze drying of a cell culture solution and a cell suspension, and the contained various stem cell secretion factors can promote the repair and regeneration of cells; the olive leaf extract, the purslane extract, the evening primrose extract and the chamomile hydrolat can relieve sensitive skin symptoms and improve skin resistance. The skin care product disclosed bythe invention can rapidly and effectively relieve anaphylactic reaction, improve the resistance of the body itself, and also can play a repair role.

The invention opened a method of exacting IgG. The method is to put the serum into the ABS then to adjust the pH by the NaOH, next to add the ethyl and PBS, last to add the (NH4)2SO4. The purity of the product is enhanced from 65% to 97%. The method can be used for the serum of rabbit, horse, sheep, chicken and mouse.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1⁺ cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.

The invention relates to a method for preparing and modifying an HEK293T cell, a modified HEK293T cell, a method for preparing drug-loaded exosome and the drug-loaded exosome. The method for preparingand modifying the HEK293T cell comprises the following steps: S1, constructing plasmids: separately constructing three plasmids, namely pcDNA3.1-STEAP3, pcDNA3.1-SDC4 and pcDNA3.1-NadB fragments by using a pcDNA3.1 expression vector as a plasmid skeleton; and S2, transfecting the three plasmids in S1 into HEK293T cells according to ratios of (1-3):(1-3):(1-3), and screening a stable cell strain to obtain a modified HEK293T cell strain. By adopting the technical scheme, due to the synergistic effect of the three plasmids, the HEK293T cells with larger exocrine secretion can be reformed, so that the exocrine secretion is further improved, and more choices are provided for clinical tests.

The present invention provides a ¹³C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-¹³C-maltose, ¹³C-starch, 1-¹³C-maltotetraose and 1-¹³C-amylose; a derivative of the ¹³C-labeled oligosaccharide or polysaccharide or salt thereof; a ¹³C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a ¹³C- or ¹⁴C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds ¹³C- or ¹⁴C-labeled.

A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

The invention discloses a separator for an extracellular secretion body. The separator comprises an operation box, an operation chamber is formed in the operation box, a base is fixedly arranged on the bottom wall of the operation chamber, a supporting column is fixedly connected to the upper side of the base, and an axis sphere is fixedly connected to the upper end face of the supporting column; and through cooperating of a power motor and a rotating plate, when an inner centrifugal barrel rotates at a low speed, oscillation is continuously generated, secretory bodies are caused to oscillate, rapid separation of the secretory bodies is promoted, the separation efficiency is improved, and impurities adsorbed on the inner wall of the separation chamber are removed when the secretory bodies are separated through cooperating of a power shaft and a sliding block. The device is simple in structure and convenient to operate, excessive loss of secretory bodies is avoided, the separation effect is improved, a three-way ball valve is matched with a filtering membrane, separated liquid obtained through screening is subjected to secondary separation, waste is avoided, meanwhile, the separated liquid can be rapidly and stably discharged, and efficiency is improved.

The invention provides an inducing medium and method for inducing fibroblasts to secrete antimicrobial peptide, the fibroblasts and application, and relates to the field of cell engineering. The inducing medium contains a basic medium, platelet lysate and a TGF-beta signal channel inhibitor. The inducing medium can activate the adipose differentiation proficiency of the skin fibroblasts and secrete the antimicrobial peptide in the adipose differentiation process. When the inducing medium is used for inducing the fibroblasts to secrete the antimicrobial peptide, operation is easy, the controllability is high, and the problem of lacking the fibroblasts capable of secreting the antimicrobial peptide in vitro in the prior art is solved.

The present invention relates to an in vitro method for generating insulin-producing beta cells from a population of mammalian cells comprising dedifferentiated exocrine pancreatic cells. The method comprises the step of culturing said dedifferentiated exocrine pancreatic cells in a culture medium in the presence of at least one agent that is able to inhibit the Notch 1 signaling pathway in said dedifferentiated exocrine pancreatic cells, and at least one ligand of the gp130 receptor and/or at least one ligand of the EGF receptor. The invention further provides a population of mammalian pancreatic cells comprising insulin-producing beta cells obtainable by the present method and uses thereof in a pharmaceutical composition for treating type 1 or type 2 diabetes.

The present disclosure relates to a composition for various applications, which is capable of effectively preventing, ameliorating or treating lupus using a secretome derived from mesenchymal stem cells.

The secretome derived from mesenchymal stem cells according to the present disclosure may significantly decrease mortality and the amount of proteinuria, and may increase body weight, decrease the expression of serum creatinine, and inhibit glomerular, coronary and vascular damage in kidney tissue. Furthermore, the secretome may reduce the size of an enlarged spleen and reduce the number of splenocytes and CD4-positive T cells. In addition, the secretome may increase the expression of the anti-inflammatory cytokines IL-10 and TGF-β1 in serum, and decrease the expression of anti-dsDNA antibody. In the mechanism thereof, the secretome may effectively prevent, ameliorate or treat lupus nephritis and, furthermore, lupus, by increasing the activity of Treg cells and inhibiting the activity of the inflammatory cells Th1 and Th2 cells, B cells, dendritic cells and inflammatory macrophages.

The present invention provides a ¹³C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-¹³C-maltose, ¹³C-starch, 1-¹³C-maltotetraose and 1-¹³C -amylose; a derivative of the ¹³C-labeled oligosaccharide or polysaccharide or salt thereof; a ¹³C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a ¹³C- or ¹⁴C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds ¹³C- or ¹⁴C-labeled.